Governance Hyperion DeFi, Inc.

HYPD

US30234E2037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-14 pm EDT			5-day change	1st Jan Change
12.03 ^USD	-9.07%		+5.71%	+3.00%

Jul. 02	Eyenovia, Inc. will Change its Name to Hyperion DeFi, Inc	CI
Jul. 02	Eyenovia, Inc. will Change its Ticker to HYPD from EYEN	CI

Executive Committee: Hyperion DeFi, Inc.

Manager

Positions heldSince

Michael Rowe

63 year

Chief Executive Officer	2022-07-31
Director of Finance/CFO	2024-11-21
Corporate Secretary	2024-11-21
Treasurer	2024-11-21

Lauren Gidden

General Counsel

2022-12-31

Composition of the Board of Directors: Hyperion DeFi, Inc.

Director

CommitteesSince

Ellen Strahlman

67 year

Audit Committee	2025-06-16
Executive Committee	2020-11-01
Governance Committee	2025-06-16
Nominating Committee	2025-06-16
Compensation Committee	2022-06-30

Michael Geltzeiler

66 year

Compensation Committee	2025-06-16
Governance Committee	2025-06-16
Nominating Committee	2025-06-16
Audit Committee Chair	2023-11-13

Rachel Jacobson

51 year

Audit Committee	2023-02-26
Compensation Committee	2025-06-16
Governance Committee Chair
Nominating Committee Chair

Michael Rowe

63 year

Director/Board Member

2022-07-31

Latest Appointments: Hyperion DeFi, Inc.

Eyenovia, Inc. Announces Board and Executive Changes	Jun. 24	CI
Eyenovia, Inc. Appoints Michael Geltzeiler to Serve on the Board and as the Chair of the Audit Committee of the Board	23-11-09	CI
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement	23-02-28	CI
Eyenovia Promotes Bren Kern to COO	22-12-08	MT
Eyenovia, Inc. Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President, Effective January 1, 2023 and Julia Haller Steps Down from its Board of Directors	22-12-08	CI
Eyenovia, Inc. Announces Retirement of Ken Lee as Lead Independent Director	22-09-30	CI
Eyenovia Names Operations Chief Michael Rowe as CEO	22-07-27	MT

More news

Former Officers and Directors: Hyperion DeFi, Inc.

Insider

Positions held

SinceUntil

Bren Kern

Chief Operating Officer

2022-07-17

2025-06-30

Charles Mather

Director/Board Member	2018-03-25	2024-08-31
Chairman	2024-08-31	2025-06-06
Independent Dir/Board Member	2018-03-25	2024-08-31

Tsontcho Ianchulev

Director/Board Member	2014-03-11	2022-02-06
Chief Executive Officer	2014-03-11	2022-07-31
Chairman	2022-02-06	-
Chief Tech/Sci/R&D Officer	2014-03-11	2022-07-31
Founder	2014-03-11	2025-06-16
President	2014-03-11	2022-02-06

Ram Palanki

Director/Board Member	2022-06-30	2025-06-16
Independent Dir/Board Member	2022-06-30	2025-06-16

Andrew Jones

Director of Finance/CFO	2024-08-29	2024-11-21
Corporate Secretary	2024-08-29	2024-11-21
Treasurer	2024-08-29	2024-11-21

Malini Batheja

Chief Tech/Sci/R&D Officer

2022-12-31

2024-10-31

John Gandolfo

Director of Finance/CFO	2017-11-30	2024-08-29
Investor Relations Contact	2017-11-30	2024-08-29
Corporate Secretary	2017-11-30	2024-08-29
Treasurer	2017-11-30	2024-08-29

Stephen Benjamin

Director/Board Member	2022-02-06	2023-02-26
Independent Dir/Board Member	-	2023-02-26

Julia Haller

Director/Board Member	2021-03-30	2022-12-05
Independent Dir/Board Member	2021-03-30	2022-12-05

Kenneth Lee

Director/Board Member	2018-03-25	2022-09-29
Independent Dir/Board Member	2018-03-25	2022-09-29

Tony Sun

Director/Board Member	2018-03-25	2022-06-15
Independent Dir/Board Member	2018-03-25	2022-06-15

Curt LaBelle

Director/Board Member

2015-05-31

2022-05-31

Ernest Mario

Director/Board Member	2014-11-30	2022-02-06
Independent Dir/Board Member	2014-11-30	2022-02-06

Fred Eshelman

Director/Board Member	2014-11-30	2017-12-31
Chairman	2017-12-31	2022-02-06
Independent Dir/Board Member	2014-11-30	2022-02-06

Shuhei Yoshida

Director/Board Member

2014-11-30

2019-06-24

Jennifer Clasby

Chief Tech/Sci/R&D Officer	2017-08-31	-
General Counsel	-	-

Luke Clauson

Chief Tech/Sci/R&D Officer

2017-07-31

Haley Butler

Corporate Secretary

Willie Deese

Chairman

Age distribution of managers

Parity Men Women

Male	6
Female	1

Of which Executive Committee

Male	2
Female	0

Of which Directors

Male	3
Female	1

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.

Employees

Sector

Pharmaceuticals

Calendar

Aug. 05 - Q2 2025 Earnings Release (Projected)

More about the company